Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction to Tenowel EM
Tenowel EM is a combination antiretroviral medication containing Tenofovir Disoproxil Fumarate (TDF) and Emtricitabine (FTC), designed to treat and prevent HIV-1 infection. It is used in antiretroviral therapy (ART) for HIV-positive individuals and as Pre-Exposure Prophylaxis (PrEP) for HIV prevention.
Uses of Tenowel EM
Part of first-line antiretroviral therapy (ART) for HIV treatment.
Used as Pre-Exposure Prophylaxis (PrEP) to prevent HIV infection.
Reduces viral replication and slows HIV disease progression.
Helps in maintaining a healthy immune system in HIV-positive patients.
Benefits of Tenowel EM
Highly effective in reducing HIV viral load when used consistently.
One-pill, once-daily regimen for convenience and adherence.
Well-tolerated with minimal side effects for most users.
Improves long-term health outcomes and quality of life.
Mechanism of Action of Tenowel EM
Tenofovir and Emtricitabine inhibit reverse transcriptase, an essential enzyme for HIV replication.
Prevents the virus from integrating into human DNA, reducing viral multiplication.
Helps maintain a suppressed viral load when used regularly.
Note: Tenowel EM should be taken under medical supervision, and regular kidney function and bone density monitoring is recommended. For PrEP use, an HIV-negative status must be confirmed before starting treatment.